title: Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation.
abstract: In previous studies we showed that a recombinant Modified Vaccinia Ankara (MVA) virus expressing the protein VP2 of AHSV serotype 4 (MVA-VP2) induced virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR-/-) against challenge. We continued these studies and determined, in the IFNAR-/- mouse model, whether the antibody responses induced by MVA-VP2 vaccination play a key role in protection against AHSV. Thus, groups of mice were vaccinated with wild type MVA (MVA-wt) or MVA-VP2 and the antisera from these mice were used in a passive immunisation experiment. Donor antisera from (a) MVA-wt; (b) MVA-VP2 vaccinated; or (c) MVA-VP2 vaccinated and AHSV infected mice, were transferred to AHSV non-immune recipient mice. The recipients were challenged with virulent AHSV together with MVA-VP2 vaccinated and MVA-wt vaccinated control animals and the levels of protection against AHSV-4 were compared between all these groups. The results showed that following AHSV challenge, mice that were passively immunised with MVA-VP2 vaccinated antisera were highly protected against AHSV disease and had lower levels of viraemia than recipients of MVA-wt antisera. Our study indicates that MVA-VP2 vaccination induces a highly protective humoral immune response against AHSV.
authors: The Pirbright Institute, Pirbright, Woking, Surrey, United Kingdom.
authors: Eva
authors: E
authors: Calvo-Pinilla
authors: Centro de Investigación en Sanidad Animal, CISA-INIA, Valdeolmos, Madrid, Spain.
authors: Francisco
authors: F
authors: de la Poza
authors: The Pirbright Institute, Pirbright, Woking, Surrey, United Kingdom.
authors: Simon
authors: S
authors: Gubbins
authors: The Pirbright Institute, Pirbright, Woking, Surrey, United Kingdom.
authors: Peter Paul Clement
authors: PP
authors: Mertens
authors: Centro de Investigación en Sanidad Animal, CISA-INIA, Valdeolmos, Madrid, Spain.
authors: Javier
authors: J
authors: Ortego
authors: The Pirbright Institute, Pirbright, Woking, Surrey, United Kingdom. Electronic address: javier.castillo-olivares@pirbright.ac.uk.
authors: Javier
authors: J
authors: Castillo-Olivares
mesh_terms: D000355:African Horse Sickness / Q000276:immunology / Q000517:prevention & control*; D000356:African Horse Sickness Virus / Q000235:genetics / Q000276:immunology*; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D004195:Disease Models, Animal; D004337:Drug Carriers; D007116:Immunization, Passive; D051379:Mice; D018345:Mice, Knockout; D014616:Vaccinia virus / Q000235:genetics*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014766:Viremia / Q000517:prevention & control
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D036022:Capsid Proteins; D004337:Drug Carriers; C442519:VP2 protein, African horse sickness virus; D014765:Viral Vaccines
keywords: African horse sickness; Humoral response; MVA-VP2; Passive immunisation; Protection; Vaccinia